GeneBioTech Co. ,Ltd (KOSDAQ:086060)
South Korea
· Delayed Price · Currency is KRW 3,160.00
+5.00 (0.16%)
At close: Mar 28, 2025, 3:30 PM KST
GeneBioTech Co. ,Ltd Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 82,959 | 79,477 | 82,759 | 62,814 | 59,119 | Upgrade
|
| Other Revenue | - | - | -0 | -0 | - | Upgrade
|
| Revenue | 82,959 | 79,477 | 82,759 | 62,814 | 59,119 | Upgrade
|
| Revenue Growth (YoY) | 4.38% | -3.96% | 31.75% | 6.25% | 1.50% | Upgrade
|
| Cost of Revenue | 69,589 | 65,825 | 72,409 | 55,374 | 49,685 | Upgrade
|
| Gross Profit | 13,370 | 13,652 | 10,349 | 7,439 | 9,435 | Upgrade
|
| Selling, General & Admin | 8,285 | 8,411 | 7,446 | 6,472 | 6,252 | Upgrade
|
| Research & Development | 875.1 | 837.22 | 765.04 | 820.81 | 1,033 | Upgrade
|
| Other Operating Expenses | 102.78 | 104.84 | 108.26 | 106.95 | 99.16 | Upgrade
|
| Operating Expenses | 9,526 | 9,679 | 8,792 | 7,893 | 10,531 | Upgrade
|
| Operating Income | 3,844 | 3,973 | 1,557 | -453.15 | -1,097 | Upgrade
|
| Interest Expense | -642.98 | -581.38 | -276.45 | -152 | - | Upgrade
|
| Interest & Investment Income | 800.59 | 669.56 | 263.92 | 127.25 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -639.97 | -138.66 | 23.26 | -223.24 | 700.7 | Upgrade
|
| Other Non Operating Income (Expenses) | 19.06 | 20.65 | 247.09 | -129.9 | -37.56 | Upgrade
|
| EBT Excluding Unusual Items | 3,380 | 3,943 | 1,815 | -831.03 | -433.68 | Upgrade
|
| Gain (Loss) on Sale of Assets | 122.26 | 20.69 | -0 | -5.88 | 13.85 | Upgrade
|
| Asset Writedown | - | -589.54 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -0.85 | - | Upgrade
|
| Pretax Income | 3,503 | 3,374 | 1,815 | -837.76 | -419.83 | Upgrade
|
| Income Tax Expense | 637.3 | 782.7 | 291.39 | -353.36 | -358.37 | Upgrade
|
| Earnings From Continuing Operations | 2,865 | 2,591 | 1,523 | -484.4 | -61.47 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | -3,370 | Upgrade
|
| Net Income to Company | 2,865 | 2,591 | 1,523 | -484.4 | -3,432 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 1,090 | Upgrade
|
| Net Income | 2,865 | 2,591 | 1,523 | -484.4 | -2,341 | Upgrade
|
| Net Income to Common | 2,865 | 2,591 | 1,523 | -484.4 | -2,341 | Upgrade
|
| Net Income Growth | 10.57% | 70.12% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Change (YoY) | -0.06% | -0.01% | - | - | - | Upgrade
|
| EPS (Basic) | 333.00 | 301.00 | 176.91 | -56.26 | -271.91 | Upgrade
|
| EPS (Diluted) | 333.00 | 301.00 | 176.91 | -56.26 | -271.91 | Upgrade
|
| EPS Growth | 10.63% | 70.14% | - | - | - | Upgrade
|
| Free Cash Flow | -1,564 | 6,838 | -4,834 | -5,816 | -1,895 | Upgrade
|
| Free Cash Flow Per Share | -181.81 | 794.31 | -561.41 | -675.39 | -220.06 | Upgrade
|
| Dividend Per Share | - | - | - | - | 30.000 | Upgrade
|
| Gross Margin | 16.12% | 17.18% | 12.50% | 11.84% | 15.96% | Upgrade
|
| Operating Margin | 4.63% | 5.00% | 1.88% | -0.72% | -1.85% | Upgrade
|
| Profit Margin | 3.45% | 3.26% | 1.84% | -0.77% | -3.96% | Upgrade
|
| Free Cash Flow Margin | -1.89% | 8.60% | -5.84% | -9.26% | -3.21% | Upgrade
|
| EBITDA | 5,212 | 5,311 | 2,843 | 791.25 | 950.17 | Upgrade
|
| EBITDA Margin | 6.28% | 6.68% | 3.44% | 1.26% | 1.61% | Upgrade
|
| D&A For EBITDA | 1,368 | 1,338 | 1,286 | 1,244 | 2,047 | Upgrade
|
| EBIT | 3,844 | 3,973 | 1,557 | -453.15 | -1,097 | Upgrade
|
| EBIT Margin | 4.63% | 5.00% | 1.88% | -0.72% | -1.85% | Upgrade
|
| Effective Tax Rate | 18.20% | 23.20% | 16.06% | - | - | Upgrade
|
| Advertising Expenses | 127.26 | 54.49 | 429.28 | 429.72 | 364.34 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.